文献速递癫痫

大麻二酚10与20 mg/kg/d辅助治疗Dravet综合征惊厥发作的剂量效应随机临床试验

Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2020-01-01

本研究为双盲安慰剂对照随机试验,纳入199例2-18岁Dravet综合征患者,评估大麻二酚10与20 mg/kg/d辅助治疗惊厥发作的疗效与安全性;结果显示两剂量较安慰剂均显著降低惊厥发作频率,10 mg/kg/d安全性更优。

要点

  • 大麻二酚10与20 mg/kg/d较安慰剂显著减少惊厥发作频率。
  • 10 mg/kg/d安全性及耐受性优于20 mg/kg/d。
  • 肝转氨酶升高多见于20 mg/kg/d且均合用丙戊酸钠者。

核心结论

  • 辅助大麻二酚10与20 mg/kg/d均使惊厥发作频率出现相似的临床相关下降,10 mg/kg/d安全性及耐受性更优。
  • 剂量增至10 mg/kg/d以上应根据个体疗效与安全性调整。

研究设计与样本

  • 筛查285例,排除86例,随机199例;198例符合条件者纳入分析(平均[SD]年龄9.3[4.4]岁;女性104例[52.5%])。
  • 随机分组:CBD10组66例、CBD20组67例、安慰剂组65例;190例完成治疗。
  • 患者年龄2至18岁,确诊Dravet综合征,基线4周内至少4次惊厥发作且至少使用1种抗癫痫药物。
  • 干预为口服大麻二酚溶液10或20 mg/kg/d(分2次等量给药)或匹配安慰剂,共14周。

主要发现

  • 惊厥发作频率较基线下降:CBD10组48.7%、CBD20组45.7%、安慰剂组26.9%。
  • 较安慰剂的下降幅度:CBD10组29.8%(95% CI, 8.4%-46.2%; P = .01),CBD20组25.7%(95% CI, 2.9%-43.2%; P = .03)。
  • 最常见不良事件为食欲下降、腹泻、嗜睡、发热和乏力。
  • CBD20组5例因不良事件停药;肝转氨酶升高在CBD20组(n = 13)多于CBD10组(n = 3),所有受累患者均合用丙戊酸钠。

临床怎么用

  • 对治疗抵抗的Dravet综合征儿童,可考虑辅助大麻二酚10 mg/kg/d,因其疗效与20 mg/kg/d相似且安全性更优。
  • 合用丙戊酸钠时需监测肝转氨酶,尤其在高剂量大麻二酚时。
  • 剂量增至10 mg/kg/d以上应基于个体疗效与安全性进行滴定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clinical evidence supports effectiveness of cannabidiol for treatment-resistant seizures in Dravet syndrome, but this trial is the first to evaluate the 10-mg/kg/d dose. OBJECTIVE: To evaluate the efficacy and safety of a pharmaceutical formulation of cannabidiol, 10 and 20 mg/kg/d, vs placebo for adjunctive treatment of convulsive seizures in patients with Dravet syndrome. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled, randomized clinical trial (GWPCARE2) recruited patients from April 13, 2015, to November 10, 2017, with follow-up completed on April 9, 2018. Of 285 patients screened from 38 centers in the United States, Spain, Poland, the Netherlands, Australia, and Israel, 86 were excluded, and 199 were randomized. Patients were aged 2 to 18 years with a confirmed diagnosis of Dravet syndrome and at least 4 convulsive seizures during the 4-week baseline period while receiving at least 1 antiepileptic drug. Data were analyzed from November 16 (date of unblinding) to December 13 (date of final outputs), 2018, based on intention to treat and per protocol. INTERVENTIONS: Patients received cannabidiol oral solution at a dose of 10 or 20 mg/kg per day (CBD10 and CBD20 groups, respectively) or matched placebo in 2 equally divided doses for 14 weeks. All patients, caregivers, investigators, and individuals assessing data were blinded to group assignment. MAIN OUTCOMES AND MEASURES: The primary outcome was change from baseline in convulsive seizure frequency during the treatment period. Secondary outcomes included change in all seizure frequency, proportion with at least a 50% reduction in convulsive seizure activity, and change in Caregiver Global Impression of Change score. RESULTS: Of 198 eligible patients (mean [SD] age, 9.3 [4.4] years; 104 female [52.5%]), 66 were randomized to the CBD10 group, 67 to the CBD20 group, and 65 to the placebo group, and 190 completed treatment. The percentage reduction from baseline in convulsive seizure frequency was 48.7% for CBD10 group and 45.7% for the CBD20 group vs 26.9% for the placebo group; the percentage reduction from placebo was 29.8% (95% CI, 8.4%-46.2%; P = .01) for CBD10 group and 25.7% (95% CI, 2.9%-43.2%; P = .03) for the CBD20 group. The most common adverse events were decreased appetite, diarrhea, somnolence, pyrexia, and fatigue. Five patients in the CBD20 group discontinued owing to adverse events. Elevated liver transaminase levels occurred more frequently in the CBD20 (n = 13) than the CBD10 (n = 3) group, with all affected patients given concomitant valproate sodium. CONCLUSIONS AND RELEVANCE: Adjunctive cannabidiol at doses of 10 and 20 mg/kg/d led to similar clinically relevant reductions in convulsive seizure frequency with a better safety and tolerability profile for the 10-mg/kg/d dose in children with treatment-resistant Dravet syndrome. Dose increases of cannabidiol to greater than 10 mg/kg/d should be tailored to individual efficacy and safety. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02224703.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Miller I, Scheffer IE, Gunning B, et al. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2020. PMID: 32119035. doi:10.1001/jamaneurol.2020.0073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。